Eledon Pharmaceuticals, Inc. (ELDN) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
The consensus price target is $5.00, representing an upside of 56.3% from the current price $3.20.
Analysts estimate Earnings Per Share (EPS) of $-0.70 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.73 vs est $-0.70 (missed -4%). 2025: actual $-0.56 vs est $-0.67 (beat +16.8%). Analyst accuracy: 88%.
ELDN Stock — 12-Month Price Forecast
$5.00
▲ +56.25% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Eledon Pharmaceuticals, Inc., the price target is $5.00.
The average price target represents a +56.25% change from the last price of $3.20.
ELDN Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Eledon Pharmaceuticals, Inc. in the past 3 months
EPS Estimates — ELDN
88%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.73
vs Est –$0.70
▼ 3.9% off
2025
Actual –$0.56
vs Est –$0.67
▲ 20.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ELDN
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
